AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-914-8420
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees49
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Avrobio (NASDAQ:AVRO) Frequently Asked Questions
What is Avrobio's stock symbol?
Avrobio trades on the NASDAQ under the ticker symbol "AVRO."
How were Avrobio's earnings last quarter?
Avrobio Inc (NASDAQ:AVRO) posted its earnings results on Thursday, August, 8th. The company reported ($0.67) EPS for the quarter, beating the Zacks' consensus estimate of ($0.76) by $0.09. View Avrobio's Earnings History.
When is Avrobio's next earnings date?
What price target have analysts set for AVRO?
6 brokerages have issued twelve-month target prices for Avrobio's stock. Their predictions range from $19.00 to $43.00. On average, they anticipate Avrobio's share price to reach $29.88 in the next year. This suggests a possible upside of 109.7% from the stock's current price. View Analyst Price Targets for Avrobio.
What is the consensus analysts' recommendation for Avrobio?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avrobio.
Has Avrobio been receiving favorable news coverage?
Media stories about AVRO stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avrobio earned a coverage optimism score of -2.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Avrobio.
Are investors shorting Avrobio?
Avrobio saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,430,000 shares, an increase of 45.2% from the August 30th total of 984,600 shares. Based on an average daily trading volume, of 379,000 shares, the short-interest ratio is presently 3.8 days. Approximately 6.3% of the company's shares are sold short. View Avrobio's Current Options Chain.
Who are some of Avrobio's key competitors?
Some companies that are related to Avrobio include Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI), SpringWorks Therapeutics (SWTX), BAVARIAN NORDIC/S (BVNRY), Twist Bioscience (TWST), AVITA MED LTD/S (RCEL), NanoString Technologies (NSTG), Rubius Therapeutics (RUBY) and Vericel (VCEL).
What other stocks do shareholders of Avrobio own?
Who are Avrobio's key executives?
Avrobio's management team includes the folowing people:
- Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 53)
- Mr. Steven N. Avruch, VP, Gen. Counsel & Sec. (Age 58)
- Mr. Jeffrey Medin Ph.D., Scientific Founder
- Mr. Erik Ostrowski, CFO & Treasurer (Age 46)
- Dr. Kim Warren, Head of Operations
When did Avrobio IPO?
(AVRO) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.
Who are Avrobio's major shareholders?
Avrobio's stock is owned by many different of institutional and retail investors. Top institutional investors include CWM LLC (0.01%). Company insiders that own Avrobio stock include Bruce Booth, Christopher Paige and Geoffrey Mackay. View Institutional Ownership Trends for Avrobio.
Which major investors are buying Avrobio stock?
How do I buy shares of Avrobio?
Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Avrobio's stock price today?
One share of AVRO stock can currently be purchased for approximately $14.25.
How big of a company is Avrobio?
Avrobio has a market capitalization of $344.14 million. The company earns $-46,360,000.00 in net income (profit) each year or ($3.62) on an earnings per share basis. Avrobio employs 49 workers across the globe.View Additional Information About Avrobio.
What is Avrobio's official website?
How can I contact Avrobio?
Avrobio's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]
MarketBeat Community Rating for Avrobio (NASDAQ AVRO)
MarketBeat's community ratings are surveys of what our community members think about Avrobio and other stocks. Vote "Outperform" if you believe AVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
